Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257410 · ClinicalTrials.gov registry record · NA
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
A NA study, sponsored by Vantive Health.
- Completed
- Registry status
- NA
- Development phase
- 172
- Enrollment target
NCT03257410 is a NA study that has completed, run by Vantive Health. The registered enrollment target is 172 participants.
The verdict
NCT03257410, a NA study, has completed, sponsored by Vantive Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 172 participants
- Enrollment target
Study Summary
The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Safety will be evaluated by maintaining pre-dialysis serum albumin levels and other safety events including laboratory tests and adverse events. Patients will undergo 3 dialysis sessions per week, for 24 weeks.
Interventions
- DEVICE Theranova 400 dialyzer
- DEVICE Elisio-17H dialyzer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2018-10-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257410
The ClinicalTrials.gov registry entry for NCT03257410 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Theranova 400 dialyzer is the first listed.
NCT03257410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03257410 about?
NCT03257410 is a clinical study titled "Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients". The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment...
What is the current status of trial NCT03257410?
This trial is currently completed. It is a NA study. The enrollment target is 172 participants. The study started on 2017-09-29. Estimated completion is 2018-10-27.
What interventions are being tested in trial NCT03257410?
The interventions under investigation include: Theranova 400 dialyzer (DEVICE), Elisio-17H dialyzer (DEVICE).
Who is sponsoring clinical trial NCT03257410?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.